• Selidji Todagbe Agnandji, Florian Kurth, Sabine Bélard, Ghyslain Mombo-Ngoma, Arti Basra, José Francisco Fernandes, Solange Solmeheim Soulanoudjingar, Akim Ayola Adegnika, and Michael Ramharter.
• Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon.
• Wien. Klin. Wochenschr. 2011 Oct 1; 123 Suppl 1: 7-9.

AbstractTimely treatment of infected children with artemisinin based combination therapies is an essential tool for the effective control and potential elimination of malaria. Until recently only tablet formulations have been available for the treatment of children leading to problems of swallowability, palatability and dosing. In consequence, paediatric drug formulations of artemisinin-based combination therapy (ACT) have been developed, showing a clinically significant improvement of tolerability in young children and of their implementation is an increasingly important public health issue. In this mini-review, we focus on the recent development of paediatric ACTs and their use in practice. Paediatric ACTs are formulated as syrup, powder for suspension, dispersible tablets and granules. Overall, the use of paediatric formulation results in an improved management of clinical malaria in young children. To date, only two paediatric ACTs have been certified with WHO prequalification status as an internationally accepted quality standard. Many more paediatric ACTs are available and in use in sub-Saharan Africa despite a lack of publicly available evidence from stringent clinical development programs. The conduct of effectiveness studies to support the introduction of paediatric ACTs in official treatment recommendations is crucial in the global strategy of malaria elimination and quality assurance of available products is a public health priority.

21 keywords...

hide…